TLR7 and neoplasm: With the TLR7 agonist Imiquimod, this vaccine generated E7-specific antitumor effects and prolonged the survival in treated mice, probably by also decreasing the number of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment of tumor-bearing mice [71].